Cancer drug can treat blindness finds HTA funded research

A cheap cancer drug is just as effective and safe in treating a common cause of loss of vision as an expensive alternative, finds research funded by the NIHR Health Technology Assessment (HTA) Programme. The two year study, which published its results in The Lancet, compared anti-cancer drug Avastin (bevacizumab) with Lucentis (ranibizumab), the drug...
Source: NIHR Evaluation, Trials and Studies News - Category: American Health Source Type: news